Physician profile
Ryan S Young
NPI 1750764239
$2,679.56
in general payments reported to CMS, 2019-2025
26 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $864 · 2023: $945 · 2024: $536 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,815.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $415.08 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $386.49 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $342.98 | 2022-2023 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $315.19 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $193.38 | 2023-2024 | Breztri, Farxiga, Airsupra |
| Neurocrine Biosciences, INC. | $180.36 | 2024 | Ingrezza |
| Bayer Healthcare Pharmaceuticals INC. | $141.31 | 2022-2023 | |
| Gilead Sciences, INC. | $117.23 | 2022-2023 | |
| Abbott Laboratories | $66.03 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $63.32 | 2023 | |
| Amgen INC. | $56.77 | 2022 | |
| Merck Sharp & Dohme LLC | $52.64 | 2022-2023 | Gardasil 9, Vaxelis, Vaxneuvance |
| Grifols USA, LLC | $46.74 | 2023-2025 | Prolastin-C Liquid |
| Shield Therapeutics INC | $38.26 | 2023 | Accrufer |
| Exact Sciences Corporation | $36.50 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $31.03 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $26.08 | 2023 | Austedo Xr, Austedo |
| Medtronic, INC. | $25.88 | 2023 | Minimed 780g |
| Novartis Pharmaceuticals Corporation | $24.46 | 2022 | |
| Livanova USA, INC. | $21.68 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Advanced Oxygen Therapy INC. | $20.73 | 2023 | Topical Oxygen Chamber For Extremities |
| Pacira Pharmaceuticals Incorporated | $19.14 | 2025 | Exparel |
| Vanda Pharmaceuticals INC. | $16.07 | 2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $15.75 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $13.49 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.